



Survivorship at 22 to 26 years reported with uncemented tapered total hip stem

By Susan M. Rapp

ORLANDO, Fla.— The results of an award-winning paper showed a loosening rate of 0.7% at 22 to 26 years follow-up for uncemented total hip arthroplasty performed with a tapered femoral component.

In his study, **Jeffrey R. McLaughlin, MD**, found one uncemented femoral stem among the 145 hips (138 patients) that were treated with total hip arthroplasty (THA) using the uncemented tapered stem (Taperloc, Biomet). William Kennedy, MD, performed all of the THA procedures between 1983 and 1985.

In a special presentation at the 26th Annual Current Concepts in Joint Replacement (CCJR) Winter Meeting, here, McLaughlin accepted the new Orthopaedic Research and Education Foundation (OREF)/CCJR Clinical Paper Award for his research. Kyla R. Lee, MD, was the co-author.

"The most striking finding of this report was the low incidence of femoral loosening at 26 years," McLaughlin said during his presentation.

The lone loose implant, which was determined based on radiographic criteria, was implanted in a patient with polio. Therefore, in patients without poliomyelitis, the aseptic loosening rate in this series was 0%, McLaughlin noted. One additional femoral component was revised for loosening 3 days postoperatively for an unrecognized intraoperative calcar fracture.

Results of other published studies corroborate these findings. Some researchers have shown 97% survivorship with the same model stems in place at roughly 18 years follow-up. Those cases included young, old and active patients, McLaughlin added.



Jeffrey R. McLaughlin, MD won the Orthopaedic Research and Education Foundations/Current Concepts in Joint Replacement Clinical Paper Award for his research.

"In our view, these are proven stems you can use in any patient," he said.

Reference:

McLaughlin JR. Uncemented total hip arthroplasty with a tapered femoral component: A 22 to 26 year follow-up study. Paper #27. Presented at the 26th Annual Current Concepts in Joint Replacement Winter Meeting. Dec. 9-12, 2009. Orlando, Fla.

Jeffrey R. McLaughlin, MD, received grant/research from and is a consultant to Biomet.